John NM, Wright SJ, Gavan SP, Vass CM. The role of information provision in economic evaluations of non-invasive prenatal testing: a systematic review. Eur J Health Econ. 2019 Nov;20(8):1123-31. doi: 10.1007/s10198-019-01082-x
Parks OB, Kothamasu KS, Ziemba MJ, Benner M, Cristinziano M, Kantz S, Leger D, Li J, Patel D, Rabuse W, Sutton S, Wilson A, Baireddy P, Kamat AA, Callas MJ, Borges MJ, Scalia MN, Klenk E, Scherer G, Martinez MM, Grubb SR, Kaufmann N, Pruitt JN, Keiser CN. Exposure to cuticular bacteria can alter host behavior in a funnel-weaving spider. Curr Zool. 2018 Dec;64(6):721-6. doi: 10.1093/cz/zox064
Wilson MR, Bergman A, Chevrou-Severac H, Selby R, Smyth M, Kerrigan MC. Cost-effectiveness of vedolizumab compared with infliximab, adalimumab, and golimumab in patients with ulcerative colitis in the United Kingdom. Eur J Health Econ. 2017 Mar;19(2):229-40. doi: 10.1007/s10198-017-0879-5.
Quinlan SC, Hawes JCL, Mines D, Ahmed S, Lanes S, Mehta V, Holick CN, Santanello N, Mast TC. Performance of an administrative claims algorithm to estimate the incidence of pure red cell aplasia in chronic hepatitis C patients. Epidemiology reports. 2015;3(1). doi: 10.7243/2054-9911-3-1
Beard SM, von Scheele BG, Nuki G, Pearson IV. Cost-effectiveness of febuxostat in chronic gout. Eur J Health Econ. 2013 May;Advance online publication.
Greiner W, Lehmann K, Earnshaw S, Bug C, Sabatowski R. Economic evaluation of Durogesic in moderate to severe, nonmalignant, chronic pain in Germany. Eur J Health Econ. 2006 Dec 1;7(4):290-6.
Lehmann K, Radbruch L, Gockel HH, Neighbors D, Nuyts G. Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Duragesic) with controlled release morphine. Eur J Health Econ. 2002;3:111-9. doi: 10.1007/s10198-002-0097-6.